Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.
For elderly patients taking statins for primary prevention, statin discontinuation is associated with an increased risk for admission for any cardiovascular event.
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Increased variations of body mass index and high-density lipoprotein cholesterol during childhood are independent risk factors for the development of diabetes.
Benefit of simvastatin-ezetimibe combo after acute coronary syndrome greatest for patients ≥75 years
The Endocrine Society published a clinical practice guideline cosponsored by the American Diabetes Association and the European Society of Endocrinology regarding the primary prevention of ASCVD and T2D.
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.
In young patients with type 1 diabetes, phenotypes of body mass index and glycemic control are associated with patterns of early diabetes complications.
Investigators sought to determine whether a monogenic cause substantially increases the risk for premature cardiovascular disease in patients with familial hypercholesterolemia.
Patients with type 2 diabetes who have had a cardiovascular event are not adequately prescribed glucose-lowering medications that might prevent subsequent CV events.
Patients with rejected or abandoned prescriptions for PCSK9i have a significantly increased risk for cardiovascular events than those with paid prescriptions.